title: A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.
abstract: BACKGROUND
  CERA, a continuous erythropoietin receptor activator, has reported effective correction of anaemia in international clinical trials.
  
  
  OBJECTIVE
  Objective of this study was to evaluate efficacy and safety of CERA in Indian patients who were on dialysis and has not received erythropoiesis stimulating agent (ESA) therapy in last 8 weeks.
  
  
  METHODS
  In this open label, single arm, prospective, multi-centre study, 189 patients on dialysis, having Haemoglobin (Hb) between 8 - 10 g/dL and not receiving any ESA for last 8 weeks were included at 14 centers across India. CERA was given intravenous (IV) at the dose of 0.6 microg/kg every two weeks. Primary end point of the study was mean change in Hb concentration from baseline to end of the treatment period (TP) of 16 weeks.
  
  
  RESULTS
  Mean change of Hb from baseline to end of TP was 2.11 +/- 1.37 g/dL and 2.08 +/- 1.29 g/dL in intent to treat (ITT) and per protocol (PP) population respectively. Mean time to achieve Hb response was 6.10 +/- 3.87 weeks and 6.16 +/- 3.92 weeks in ITT and PP populations respectively. Out of 68 adverse events (AEs) seen during study period, 33 were serious adverse events (SAEs). As per investigators all SAEs were related to underlying disease and not to the study medication.
  
  
  CONCLUSIONS
  It is concluded that CERA administered once in two weeks in dialysis patients effectively corrected chronic kidney disease (CKD) related anaemia and was well tolerated with no significant untoward effect directly related to drug therapy in Indian population.
authors.forename: Georgy K
authors.initials: GK
authors.lastname: Nainan
authors.forename: Vivek R
authors.initials: VR
authors.lastname: Pathak
authors.forename: Sonal S
authors.initials: SS
authors.lastname: Dalal
authors.forename: Sanjiv
authors.initials: S
authors.lastname: Saxena
authors.forename: Dinesh
authors.initials: D
authors.lastname: Mittal
authors.forename: T Ravi
authors.initials: TR
authors.lastname: Raju
authors.lastname: Gokulnath
authors.forename: Rajan
authors.initials: R
authors.lastname: Isaac
authors.forename: M M
authors.initials: MM
authors.lastname: Rajapurkar
authors.forename: D S
authors.initials: DS
authors.lastname: Rana
authors.forename: Bharat V
authors.initials: BV
authors.lastname: Shah
authors.forename: Deepak S
authors.initials: DS
authors.lastname: Ray
authors.forename: C M
authors.initials: CM
authors.lastname: Thiagarajan
authors.forename: Ratan M
authors.initials: RM
authors.lastname: Jha
authors.forename: Anil A
authors.initials: AA
authors.lastname: Kukreja
authors.forename: Rupesh R
authors.initials: RR
authors.lastname: Pophale
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011446:Prospective Studies; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: C508420:continuous erythropoietin receptor activator; D004921:Erythropoietin; D011092:Polyethylene Glycols